search
Back to results

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Omalizumab
Inhaled corticosteroids (ICS)
Long-acting beta 2-adrenergic agonist (LABA)
Short-acting beta 2-adrenergic agonist (SABA)
Sponsored by
Novartis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, anti-immunoglobulin E, omalizumab

Eligibility Criteria

12 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • 12 to 75 years-old during screening visit.
  • Body weight > 20 kg and < 150 kg.
  • Daily or persistent asthma symptoms.
  • Night symptoms at least once a week.
  • Forced expiratory volume in 1 second (FEV1) > 40% and < 80% of predicted normal value and continuing asthma symptoms.
  • FEV1 increased > 12% from baseline within 30 minutes of inhaled (up to 400 mcg) or nebulized (up to 5 mg) salbutamol.
  • Subject taking more than 500 mcg/day of fluticasone or equivalent associated to a long-acting β2-agonist.
  • Inhaled corticosteroid and long-acting beta-2 adrenergic agonist (LABA) doses that remained fixed during the last 12 weeks prior to screening.
  • Medical history of at least two episodes of asthma exacerbation treated with systemic corticoid or at least one severe asthma exacerbation treated with systemic corticoid and hospitalization or emergency room visit in the last 12 months prior to screening.
  • Positive skin prick test (diameter of wheal > 3mm) to at least one perennial aeroallergen (dust mite, cat/dog dander, cockroaches), to which the subject was likely to be exposed during the study.
  • Subject capable to read and understand asthma related quality of life questionnaire (Juniper's questionnaire).

Exclusion criteria:

  • Pregnant, nursing female subjects.
  • Female subjects without current acceptable contraceptive method.
  • Previous history of allergy or hypersensitivity to omalizumab.
  • Subjects with prior treatment with omalizumab.
  • Subjects with medical history of psychiatric disorder.
  • Subject had been treated with systemic corticosteroid for any reason other than asthma.
  • Subject took β2 antagonist medication in the last 3 months prior to screening visit.
  • Subject took protocol prohibited medication prior to screening.
  • Medical history of food or drug related severe anaphylactoid reactions.
  • Medical history of antibiotics allergy. Patients were included if the antibiotics to which they were allergic to were to be avoided for the entire duration of the study.
  • Asthma related to non-steroidal anti-inflammatory drug (NSAID).
  • Treatment of exacerbation in the 4 weeks prior to randomization.
  • Other active lung diseases.
  • Medical history of others uncontrolled diseases 3 months prior randomization (eg, infections, coronary heart diseases and metabolic diseases).
  • Any history of cancer.
  • Abnormal electrocardiogram (ECG), laboratory exams (clinically significant abnormalities), and chest X-ray (CXR).
  • Evidence or history of drug or alcohol abuse.
  • Airway infection (eg, pneumonia, acute sinusitis) 4 weeks prior to screening visit.
  • Smokers or smoking history of > 10 pack-years.
  • Subject that had been treated with investigational drugs over the past 30 days or during the course of the trial.
  • Subject had elevated IgE levels for reasons other than allergy.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Sites / Locations

  • Novartis Investigator Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Omalizumab + Conventional Therapy

Conventional Therapy

Arm Description

Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.

Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.

Outcomes

Primary Outcome Measures

The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment.

Secondary Outcome Measures

Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
The Mean Change From Baseline to the End of Study in AQLQ Domain Score
AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration. The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment.
Number of Asthma Exacerbation Episodes Per Participant
For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode.
Percentage of Participants Using Rescue Medication
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm.
Free Days With no Rescue Medication
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis.
Mean Number of Puffs of Rescue Medication Taken Per Day
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day.
Physician's Global Assessment of Treatment Effectiveness
At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma
Patient's Global Assessment of Treatment Effectiveness
At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma

Full Information

First Posted
December 4, 2007
Last Updated
June 28, 2011
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT00567476
Brief Title
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
Official Title
A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, anti-immunoglobulin E, omalizumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
116 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Omalizumab + Conventional Therapy
Arm Type
Active Comparator
Arm Description
Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
Arm Title
Conventional Therapy
Arm Type
Active Comparator
Arm Description
Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
Intervention Type
Drug
Intervention Name(s)
Omalizumab
Other Intervention Name(s)
Xolair
Intervention Description
Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
Intervention Type
Drug
Intervention Name(s)
Inhaled corticosteroids (ICS)
Intervention Description
Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
Intervention Type
Drug
Intervention Name(s)
Long-acting beta 2-adrenergic agonist (LABA)
Intervention Description
Fixed dose of LABA as prescribed prior to study entry
Intervention Type
Drug
Intervention Name(s)
Short-acting beta 2-adrenergic agonist (SABA)
Other Intervention Name(s)
salbutamol, terbutaline
Intervention Description
Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Primary Outcome Measure Information:
Title
The Mean Change From Baseline to Week 20 in the Overall Asthma Quality of Life Questionnaire (AQLQ)
Description
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and a score of 1.0 indicates severe impairment.
Time Frame
Baseline and Week 20
Secondary Outcome Measure Information:
Title
Percentage of Participants With an Increase of More Than 1.5 in AQLQ Overall Score at 20 Weeks
Description
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
Time Frame
Baseline and Week 20
Title
Percentage of Participants With an Increase of More Than 0.5 in AQLQ Overall Score at Week 20
Description
The AQLQ was administered to all patients at Baseline, Week 12 and Week 20. The 32 questions in the AQLQ were divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. AQLQ of each domain is the mean of the responses to each of the questions within that domain. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
Time Frame
Baseline and Week 20
Title
The Mean Change From Baseline to the End of Study in AQLQ Domain Score
Description
AQLQ was administered to all patients at Baseline, Week 12 and Week 20, and prior to any clinic visit evaluation and drug administration. The 32 questions in the AQLQ were divided into four domains: activity limitations, symptoms, emotional function, and environmental stimuli. AQLQ domain scores were calculated by adding the responses to each of the questions in the domain and dividing by the number of questions in the domain. Each domain score was between 1 and 7. Score 7.0 meant that the patient had no impairments due to asthma and score 1.0 indicated severe impairment.
Time Frame
Baseline and Week 20
Title
Number of Asthma Exacerbation Episodes Per Participant
Description
For the purpose of evaluating efficacy, a clinically significant asthma exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling the baseline ICS dose for at least 3 days and/or treatment with rescue systemic (oral or IV) corticosteroids. The initiation of the above corticosteroid regimens marked the start of an asthma exacerbation episode and cessation of the additional corticosteroid regimens marked the end of an exacerbation episode.
Time Frame
From Baseline through 20 weeks
Title
Percentage of Participants Using Rescue Medication
Description
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm.
Time Frame
From Baseline through 20 Weeks
Title
Free Days With no Rescue Medication
Description
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. Days with no rescue medication intake were the variable of interest for this analysis.
Time Frame
From Baseline through 20 weeks (140 days)
Title
Mean Number of Puffs of Rescue Medication Taken Per Day
Description
When necessary, patients were allowed to take rescue medication using inhaled salbutamol or terbutaline for symptoms of intercurrent bronchospasm. The number of puffs taken during each 24 hour period was recorded in the patient dairy. The total number of puffs over 20 weeks of treatment was divided by the number of treatment days (140 days) to calculate the mean number of puffs per day.
Time Frame
From Baseline through 20 Weeks
Title
Physician's Global Assessment of Treatment Effectiveness
Description
At the end of Week 20 a global evaluation of the treatment effectiveness was performed by the investigator using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma
Time Frame
20 Weeks
Title
Patient's Global Assessment of Treatment Effectiveness
Description
At the end of Week 20, a global evaluation of the treatment effectiveness was performed by the patient using the following scale: Excellent: complete control of asthma; Good: marked improvement of asthma; Moderate: discernible, but limited improvement in asthma; Poor: no appreciable change in asthma; Worsening of asthma
Time Frame
20 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: 12 to 75 years-old during screening visit. Body weight > 20 kg and < 150 kg. Daily or persistent asthma symptoms. Night symptoms at least once a week. Forced expiratory volume in 1 second (FEV1) > 40% and < 80% of predicted normal value and continuing asthma symptoms. FEV1 increased > 12% from baseline within 30 minutes of inhaled (up to 400 mcg) or nebulized (up to 5 mg) salbutamol. Subject taking more than 500 mcg/day of fluticasone or equivalent associated to a long-acting β2-agonist. Inhaled corticosteroid and long-acting beta-2 adrenergic agonist (LABA) doses that remained fixed during the last 12 weeks prior to screening. Medical history of at least two episodes of asthma exacerbation treated with systemic corticoid or at least one severe asthma exacerbation treated with systemic corticoid and hospitalization or emergency room visit in the last 12 months prior to screening. Positive skin prick test (diameter of wheal > 3mm) to at least one perennial aeroallergen (dust mite, cat/dog dander, cockroaches), to which the subject was likely to be exposed during the study. Subject capable to read and understand asthma related quality of life questionnaire (Juniper's questionnaire). Exclusion criteria: Pregnant, nursing female subjects. Female subjects without current acceptable contraceptive method. Previous history of allergy or hypersensitivity to omalizumab. Subjects with prior treatment with omalizumab. Subjects with medical history of psychiatric disorder. Subject had been treated with systemic corticosteroid for any reason other than asthma. Subject took β2 antagonist medication in the last 3 months prior to screening visit. Subject took protocol prohibited medication prior to screening. Medical history of food or drug related severe anaphylactoid reactions. Medical history of antibiotics allergy. Patients were included if the antibiotics to which they were allergic to were to be avoided for the entire duration of the study. Asthma related to non-steroidal anti-inflammatory drug (NSAID). Treatment of exacerbation in the 4 weeks prior to randomization. Other active lung diseases. Medical history of others uncontrolled diseases 3 months prior randomization (eg, infections, coronary heart diseases and metabolic diseases). Any history of cancer. Abnormal electrocardiogram (ECG), laboratory exams (clinically significant abnormalities), and chest X-ray (CXR). Evidence or history of drug or alcohol abuse. Airway infection (eg, pneumonia, acute sinusitis) 4 weeks prior to screening visit. Smokers or smoking history of > 10 pack-years. Subject that had been treated with investigational drugs over the past 30 days or during the course of the trial. Subject had elevated IgE levels for reasons other than allergy. Other protocol-defined inclusion/exclusion criteria applied to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharma
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Chair
Facility Information:
Facility Name
Novartis Investigator Site
City
São Paulo
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

We'll reach out to this number within 24 hrs